<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35602105</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1942-0994</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>2022</Volume>
            <PubDate>
              <Year>2022</Year>
            </PubDate>
          </JournalIssue>
          <Title>Oxidative medicine and cellular longevity</Title>
          <ISOAbbreviation>Oxid Med Cell Longev</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Apatinib Induces Ferroptosis of Glioma Cells through Modulation of the VEGFR2/Nrf2 Pathway.</ArticleTitle>
        <Pagination>
          <StartPage>9925919</StartPage>
          <MedlinePgn>9925919</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">9925919</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1155/2022/9925919</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Glioma is a common tumor that originated from the brain, and molecular targeted therapy is one of the important treatment modalities of glioma. Apatinib is a small-molecule tyrosine kinase inhibitor, which is widely used for the treatment of glioma. However, the underlying molecular mechanism has remained elusive. Recently, emerging evidence has proved the remarkable anticancer effects of ferroptosis. In this study, a new ferroptosis-related mechanism of apatinib inhibiting proliferation of glioma cells was investigated, which facilitated further study on inhibitory effects of apatinib on cancer cells.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Human glioma U251 and U87 cell lines and normal astrocytes were treated with apatinib. Ferroptosis, cell cycle, apoptosis, and proliferation were determined. A nude mouse xenograft model was constructed, and tumor growth rate was detected. Tumor tissues were collected to estimate ferroptosis levels and to identify the relevant pathways after treatment with apatinib.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Treatment with apatinib could induce loss of cell viability of glioma cells, but not of normal astrocytes, through eliciting ferroptosis in vitro and in vivo. It was also revealed that apatinib triggered ferroptosis of glioma cells via inhibiting the activation of nuclear factor erythroid 2-related factor 2/vascular endothelial growth factor receptor 2 (Nrf2/VEFGR2) pathway. The overexpression of Nrf2 rescued the therapeutic effects of apatinib.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Our study proved that treatment with apatinib could restrain proliferation of glioma cells through induction of ferroptosis via inhibiting the activation of VEGFR2/Nrf2/Keap1 pathway. Overexpression of Nrf2 could counteract the induction of ferroptosis by apatinib.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Liang Xia et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Xia</LastName>
            <ForeName>Liang</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Head &amp; Neck Cancer, Translational Research of Zhejiang Province, Hangzhou 310022, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Gong</LastName>
            <ForeName>Mingjie</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Changshu No. 2 People's Hospital, The Affiliated Changshu Hospital of Xuzhou Medical University, Changshu 215500, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Zou</LastName>
            <ForeName>Yangfan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Zeng</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Bin</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Shuyuan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Liwen</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jin</LastName>
            <ForeName>Kai</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Caixing</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0001-9857-5416</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Head &amp; Neck Cancer, Translational Research of Zhejiang Province, Hangzhou 310022, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Oxid Med Cell Longev</MedlineTA>
        <NlmUniqueID>101479826</NlmUniqueID>
        <ISSNLinking>1942-0994</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000072019">Kelch-Like ECH-Associated Protein 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5S371K6132</RegistryNumber>
          <NameOfSubstance UI="C553458">apatinib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D040301">Vascular Endothelial Growth Factor Receptor-2</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="Y">Ferroptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005910" MajorTopicYN="Y">Glioma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072019" MajorTopicYN="N">Kelch-Like ECH-Associated Protein 1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D040301" MajorTopicYN="N">Vascular Endothelial Growth Factor Receptor-2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare that there is no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>23</Day>
          <Hour>4</Hour>
          <Minute>21</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35602105</ArticleId>
        <ArticleId IdType="pmc">PMC9117021</ArticleId>
        <ArticleId IdType="doi">10.1155/2022/9925919</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Efimova I., Catanzaro E., Van der Meeren L., et al.  Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. 
Journal for Immunotherapy of Cancer
. 2020;8(2, article e001369) doi: 10.1136/jitc-2020-001369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2020-001369</ArticleId>
            <ArticleId IdType="pmc">PMC7668384</ArticleId>
            <ArticleId IdType="pubmed">33188036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu H.-j., Hu H.-m., Li G.-z., et al.  Ferroptosis-related gene signature predicts glioma cell death and glioma patient progression. 
Developmental Biology
. 2020;8:p. 538. doi: 10.3389/fcell.2020.00538.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcell.2020.00538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell B. R., Angeli J. P. F., Bayir H., et al.  Ferroptosis: a regulated cell death nexus linking Metabolism, Redox Biology, and Disease. 
Cell
. 2017;171(2):273–285. doi: 10.1016/j.cell.2017.09.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.021</ArticleId>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Z., Mi Y., Qian H., et al.  A potential mechanism of temozolomide resistance in glioma-ferroptosis. 
Frontiers in Oncology
. 2020;10:p. 897. doi: 10.3389/fonc.2020.00897.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2020.00897</ArticleId>
            <ArticleId IdType="pmc">PMC7324762</ArticleId>
            <ArticleId IdType="pubmed">32656078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang J., Gu W., Jin J., et al.  Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study. 
Therapeutic Advances in Medical Oncology
. 2020;12, article 175883592096847 doi: 10.1177/1758835920968472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1758835920968472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu H., Li J., You N., et al.  Efficacy and safety of apatinib combined with transarterial chemoembolization (TACE) in treating patients with recurrent hepatocellular carcinoma. 
Ann Transl Med
. 2020;8(24):p. 1677. doi: 10.21037/atm-20-7244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/atm-20-7244</ArticleId>
            <ArticleId IdType="pmc">PMC7812192</ArticleId>
            <ArticleId IdType="pubmed">33490189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang C., Jiang M., Hou H., Lin Q., Yan Z., Zhang X. Apatinib suppresses cell growth and metastasis and promotes antitumor activity of temozolomide in glioma. 
Oncology Letters
. 2018;16(5):5607–5614. doi: 10.3892/ol.2018.9355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2018.9355</ArticleId>
            <ArticleId IdType="pmc">PMC6176256</ArticleId>
            <ArticleId IdType="pubmed">30344715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao L., Peng Y., He S., et al.  Apatinib induced ferroptosis by lipid peroxidation in gastric cancer. 
Gastric Cancer
. 2021;24(3):642–654. doi: 10.1007/s10120-021-01159-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10120-021-01159-8</ArticleId>
            <ArticleId IdType="pubmed">33544270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiang Z., Dong H., Xia Y., Chai D., Hu R., Jiang H. Nrf2 and STAT3 alleviates ferroptosis-mediated IIR-ALI by regulating SLC7A11. 
Oxidative Medicine and Cellular Longevity
. 2020;2020:16. doi: 10.1155/2020/5146982.5146982</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2020/5146982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen R., Smith-Cohn M., Cohen A. L., Colman H. Glioma subclassifications and their clinical significance. 
Neurotherapeutics
. 2017;14(2):284–297. doi: 10.1007/s13311-017-0519-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13311-017-0519-x</ArticleId>
            <ArticleId IdType="pmc">PMC5398991</ArticleId>
            <ArticleId IdType="pubmed">28281173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu D., Han G., Liu H., Gao L., Verma V. Treatment of adult brainstem glioma with combined antiangiogenic therapy: a case report and literature review. 
Oncotargets and Therapy
. 2019;12:1333–1339. doi: 10.2147/OTT.S195783.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S195783</ArticleId>
            <ArticleId IdType="pmc">PMC6388961</ArticleId>
            <ArticleId IdType="pubmed">30863099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H., Chen F., Wang Z., Wu S. Successful treatment with apatinib for refractory recurrent malignant gliomas: a case series. 
Oncotargets and Therapy
. 2017;10:837–845. doi: 10.2147/OTT.S119129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S119129</ArticleId>
            <ArticleId IdType="pmc">PMC5317326</ArticleId>
            <ArticleId IdType="pubmed">28243119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X., Zheng Q., Yu Q., et al.  Apatinib regulates the growth of gastric cancer cells by modulating apoptosis and autophagy. 
Naunyn-Schmiedeberg's Archives of Pharmacology
. 2021;394</Citation>
        </Reference>
        <Reference>
          <Citation>Chen X., Kang R., Kroemer G., Tang D. Broadening horizons: the role of ferroptosis in cancer. 
Nature Reviews Clinical Oncology
. 2021;18(5)</Citation>
        </Reference>
        <Reference>
          <Citation>Yan H. F., Zou T., Tuo Q. Z., et al.  Ferroptosis: mechanisms and links with diseases. 
Signal Transduction and Targeted Therapy
. 2021;6(1):p. 49. doi: 10.1038/s41392-020-00428-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41392-020-00428-9</ArticleId>
            <ArticleId IdType="pmc">PMC7858612</ArticleId>
            <ArticleId IdType="pubmed">33536413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park E., Chung S. W. ROS-mediated autophagy increases intracellular iron levels and ferroptosis by ferritin and transferrin receptor regulation. 
Cell Death &amp; Disease
. 2019;10(11):p. 822. doi: 10.1038/s41419-019-2064-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-019-2064-5</ArticleId>
            <ArticleId IdType="pmc">PMC6817894</ArticleId>
            <ArticleId IdType="pubmed">31659150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sui X., Zhang R., Liu S., et al.  RSL3 drives ferroptosis through GPX4 inactivation and ROS production in colorectal cancer. 
Frontiers in Pharmacology
. 2018;9:p. 1371. doi: 10.3389/fphar.2018.01371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2018.01371</ArticleId>
            <ArticleId IdType="pmc">PMC6262051</ArticleId>
            <ArticleId IdType="pubmed">30524291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao G., Xie Z., Li E. W., et al.  Dehydroabietic acid improves nonalcoholic fatty liver disease through activating the Keap 1/Nrf2-ARE signaling pathway to reduce ferroptosis. 
Journal of Natural Medicines
. 2021;75(3):540–552. doi: 10.1007/s11418-021-01491-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11418-021-01491-4</ArticleId>
            <ArticleId IdType="pubmed">33590347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y., Zhao Y., Yang H.-z., Wang Y.-j., Chen Y. HMGB1 regulates ferroptosis through Nrf2 pathway in mesangial cells in response to high glucose. 
Bioscience Reports
. 2021;41(2) doi: 10.1042/BSR20202924.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BSR20202924</ArticleId>
            <ArticleId IdType="pmc">PMC7897919</ArticleId>
            <ArticleId IdType="pubmed">33565572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan Z., Wirth A. K., Chen D., et al.  Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis. 
ONCOGENESIS
. 2017;6(8, article e371) doi: 10.1038/oncsis.2017.65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/oncsis.2017.65</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roh J. L., Kim E. H., Jang H., Shin D. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. 
Redox Biology
. 2017;11:254–262. doi: 10.1016/j.redox.2016.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.redox.2016.12.010</ArticleId>
            <ArticleId IdType="pmc">PMC5198738</ArticleId>
            <ArticleId IdType="pubmed">28012440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X., Ou Z., Chen R., Niu X., De Chen R. K., Tang D. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. 
Hepatology
. 2016;63(1):173–184. doi: 10.1002/hep.28251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.28251</ArticleId>
            <ArticleId IdType="pmc">PMC4688087</ArticleId>
            <ArticleId IdType="pubmed">26403645</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
